Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines

Schijns, Virgil E.J.C.; Tartour, Éric; Michálek, Jaroslav; Stathopoulos, Apostolos; Dobrovolskiene, Neringa; Strioga, Marius

doi:10.1016/j.jcyt.2013.09.008

Cited by 28 publications

(20 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…144). Recent data show that mucosal cancers are best treated by vaccines that endow T cells with mucosal homing properties (145), but much more work is needed before solid rules for more efficient homing to cancerous tissues are incorporated into human cancer vaccine designs.…”

Section: Guidelines For the Development Of Successful Therapeutic Canmentioning

confidence: 99%

Therapeutic cancer vaccines

Melief

Hall

Arens

et al. 2015

Journal of Clinical Investigation

709

409

View full text Add to dashboard Cite

Conflict of interest: Cornelis J.M. Melief is fully employed as Chief Scientific Officer of ISA Pharmaceuticals and has stock appreciation rights in the company. Cornelis Melief and Sjoerd H. van der Burg are co-inventors on numerous patents and patent applications in the area of synthetic long peptide vaccines. Clinical trials conducted by Melief and van der Burg with synthetic long peptides have been funded by the Dutch Cancer Society and by ISA Pharmaceuticals.

show abstract

Section: Guidelines For the Development Of Successful Therapeutic Canmentioning

confidence: 99%

Therapeutic cancer vaccines

Melief

Hall

Arens

et al. 2015

Journal of Clinical Investigation

709

409

View full text Add to dashboard Cite

show abstract

“…, immature and the mature DC. Immature DCs (imDCs) effectively capture and process antigen but limitedly express allostimulatory molecules (CD40, CD80 and CD86), whereas mature DCs (mDCs) can be generated from imDCs by stimulations from toll-like receptors (TLRs) and have a higher expression of costimulatory molecules as well as an elevated ability to home to lymph nodes (LNs)2.…”

mentioning

confidence: 99%

Mature dendritic cell derived from cryopreserved immature dendritic cell shows impaired homing ability and reduced anti-viral therapeutic effects

Zhou

Zhao

Wang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Cryopreservation is critical in reducing redundant operations and also in quality control in dendritic cell (DC) therapy. Full maturation and efficient homing of DCs to T cell-region constitute a crucial aspect of DC immunotherapy; however, the in vivo migration and distribution pattern, as well as the anti-viral effect of DCs that matured from cryopreserved immature DCs (cryoim-mDCs) remain to be revealed. In the present study, we compared cryoim-mDCs with DCs matured from fresh immature DCs (fmDCs) in the aspects of phenotypes, in vivo homing capacities as well as the anti-viral therapeutic effects to further clarify the effect of cryopreservation on DC-based cytotherapy. The results showed that cryopreservation impaired the homing ability of DCs which was associated with the reduced expression of CCR7 and disturbed cytoskeleton arrangement. Moreover, the antigen-specific CD8+ T cell response induced by cryoim-mDCs was much weaker than that induced by fmDCs in both the spleen and liver draining lymph nodes, which provided reduced protection from viral invasions. In conclusion, cryopreservation is a good method to keep the viability of immature DCs, however, the in vivo homing capacity and anti-viral therapeutic effect of DCs matured from frozen immature DCs were hindered to some extent.

show abstract

“…Various preventive and therapeutic vaccines are generally used with vaccine adjuvants that shape and potentiate the induced immune responses, thereby increasing the efficacy of vaccination (45,46). In a previously investigated metastatic LLC model, where B. subtilis was used as an adjuvant for an autologous tumour lysate-based vaccine, it failed to demonstrate satisfactory clinical benefits (39); an underperformance repeated in the present study.…”

Section: Discussionmentioning

confidence: 71%

“…In addition, distinct spectrum of TAAs in B16 melanoma and LCC lung cancer cells may be responsible for the xeno rat vaccine exhibiting (39), and this underperformance was repeated in the present study. Various vaccines (preventive and therapeutic) are generally used with vaccine adjuvants that shape and potentiate the induced immune responses, thereby increasing the efficacy of vaccination (45,46). The present study, however, demonstrates that a unadjuvanted xenogeneic vaccine (xeno chicken) can be successfully applied, and the xenogeneic component of the vaccine can serve as sufficient adjuvant on in its own right.…”

Section: Discussionmentioning

confidence: 71%

Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model

et al. 2018

View full text Add to dashboard Cite

Abstract. Immunotherapy in the form of anticancer vaccination relies on the mobilization of the patient's immune system against specific cancer antigens. Instead of focusing on an autologous cell lysate, which is not always available in clinical practice, the present study investigates vaccines utilizing xenogeneic foetal tissue that are rich in oncofoetal antigens. Lewis lung carcinoma (LLC)-challenged C57BL/6 mice were treated with either a xenogeneic vaccine made from chicken whole embryo, or a xenogeneic vaccine made from rat embryonic brain tissue, supplemented with a Bacillus subtilis protein fraction as an adjuvant. Median and overall survival, size of metastatic foci in lung tissue and levels of circulating CD8a + T cells were evaluated and compared with untreated control mice. Following primary tumour removal, a course of three subcutaneous vaccinations with xenogeneic chicken embryo vaccine led to significant increase in overall survival rate (100% after 70 days of follow-up vs. 40% in untreated control mice), significant increase in circulating CD8a + T cells (18.18 vs. 12.6% in untreated control mice), and a significant decrease in the area and incidence of metastasis foci. The xenogeneic rat brain tissue-based vaccine did not improve any of the investigated parameters, despite promising reports in other models. We hypothesize that the proper selection of antigen source (tissue) can constitute an effective immunotherapeutic product.

show abstract

Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines

Cited by 28 publications

References 84 publications

Therapeutic cancer vaccines

Therapeutic cancer vaccines

Mature dendritic cell derived from cryopreserved immature dendritic cell shows impaired homing ability and reduced anti-viral therapeutic effects

Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model

Contact Info

Product

Resources

About